Ixazomib receives FDA priority review for myeloma

Takeda, the Japanese pharmaceutical company, has announced that the US Food and Drug Administration (FDA) has granted Priority Review status to its New Drug Application for ixazomib as a treatment for relapsed and/or refractory myeloma patients. The application was based primarily on interim results from the pivotal Phase III TOURMALINE-MM1 trial comparing ixazomib in combination…

Details

Study demonstrates superiority of SKY92 genetic signature over other prognostic markers

A study, published recently in Blood, has found that the SKY92-signature (EMC92) for genetic subtyping of myeloma patients in combination with the International Staging System (ISS) classification is a stronger predictor for overall survival compared to other existing classifiers. The SKY92-signature developed by the Erasmus Medical Centre, Rotterdam, consisted of 92 genes directly or indirectly…

Details